Vertex Announces Participation in UBS Global Healthcare Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its leadership will participate in the UBS Global Healthcare Conference, underscoring the company’s ongoing efforts to advance treatments for serious diseases and its robust clinical program. Reshma Kewalramani, Ph.D., Chief Executive Officer and President, is slated to take part in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET. The event provides Vertex with a platform to harmonize its strategic priorities with the needs of patients, clinicians, and investors.
What to Expect from the Fireside Chat
The fireside chat will offer insights into Vertex’s current and upcoming programs, including approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. It will also highlight Vertex’s ongoing exploration across a broad clinical pipeline spanning cystic fibrosis-related targets, kidney disease, neuropathic pain, and other serious conditions. Investors and stakeholders can anticipate discussions on advancing science-driven solutions and Vertex’s approach to tackling complex diseases through precision medicine.
Key Topics That May Be Covered
- Progress and milestones for existing therapies and patient outcomes.
- Updates on the company’s diverse, modality-spanning pipeline in areas such as nephrology, diabetes, and genetic diseases.
- Strategic priorities for long-term growth, including partnerships, regulatory expectations, and manufacturing scalability.
- Vertex’s culture of scientific innovation and commitment to being a leading employer in the biotechnology sector.
About Vertex
Vertex is a global biotechnology company focused on creating transformative medicines for people with serious diseases. The company’s approved therapies target cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Vertex continues to advance a broad and advancing clinical pipeline across multiple modalities, targeting areas with deep insight into causal human biology. These efforts include research into neuropathic pain, kidney diseases such as APOL1-mediated kidney disease and IgA nephropathy, as well as autoimmune and metabolic conditions like type 1 diabetes and myotonic dystrophy type 1.
Corporate Footprint and Workplace Recognition
Founded in 1989, Vertex is headquartered in Boston, with international headquarters in London and multiple research, development, and commercial offices across North America, Europe, Australia, Latin America, and the Middle East. The company has earned recognition for corporate culture and workplace excellence, including 16 consecutive years on Science magazine’s Top Employers list and a place among Fortune’s 100 Best Companies to Work For.
Where to Access Live and Archived Content
A live webcast of Vertex’s remarks at the UBS Global Healthcare Conference will be available on Vertex’s website under the Investors section, News and Events. A replay of the conference webcast will be archived on Vertex’s site for on-demand viewing. For the latest company updates, investors and the media can visit vrtx.com and follow Vertex on LinkedIn, Facebook, Instagram, YouTube, and X.
Contact information for investors is available at InvestorInfo@vrtx.com.
